Oxalic Acid

Oxalic Acid

SCHEMBL7609511

CN1CCC=C(c2nsnc2Cl)C1.O=C(O)C(=O)O

nearest known ligand 0.84

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7612125 0.92 CHRM1 (1.00) CHRM1
Hydrochloric Acid SCHEMBL23359148 0.90 CHRM1 (0.97) CHRM1
Oxalic Acid SCHEMBL7619183 0.83 CHRM1 (0.58) CHRM1
Oxalic Acid SCHEMBL7611790 0.82 CHRM1 (0.70) CHRM1
Oxalic Acid SCHEMBL7617351 0.82 CHRM1 (0.85) CHRM1
Oxalic Acid SCHEMBL7618760 0.81 CHRM1 (0.56) CHRM1
Oxalic Acid SCHEMBL7617871 0.80 CHRM1 (0.70) CHRM1
Oxalic Acid SCHEMBL7612877 0.79 CHRM1 (0.86) CHRM1
Oxalic Acid SCHEMBL7611848 0.79 CHRM1 (0.66) CHRM1
Oxalic Acid SCHEMBL7642278 0.79 CHRM1 (0.57) CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP disclosed
US-5773452-A ALZHEIMER'S DISEASE; COGNITION ACTIVATORS NOVO NORDISK ALS (DK) 1998-06-30 US disclosed
US-5753683-A SCHIZOPHRENIA NOVO NORDISK A/S (DK) 1998-05-19 US disclosed
US-5750541-A 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION NOVO NORDISK A/S (DK) 1998-05-12 US disclosed
US-5744489-A ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS GREENWOOD BEVERLEY (US) 1998-04-28 US disclosed
US-5712297-A COGNITION ACTIVATORS; ALZHEIMER*S DISEASE NOVO NORDISK A/S (DK) 1998-01-27 US disclosed
EP-0788357-A1 A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS NOVO NORDISK A/S (DK) 1997-08-13 EP disclosed
US-5565475-A Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives MUHLHAUSER MARK A (US) 1996-10-15 US disclosed
EP-0734259-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-10-02 EP disclosed
EP-0732925-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1996-09-25 EP disclosed
EP-0384288-B1 Piperidine compounds and their preparation and use NOVO NORDISK AS (DK) 1995-05-24 EP disclosed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed
WO-1994020495-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO disclosed
US-5328925-A Alzheimer*s disease NOVO NORDISK A/S (DK) 1994-07-12 US disclosed
US-5284859-A Analgesics, Alzheimer's disease NOVO NORDISK A/S (DK) 1994-02-08 US disclosed
US-5264444-A Cognition activators NOVO NORDISK A/S (DK) 1993-11-23 US disclosed
US-5260311-A Cognition activators, analgesics for sever pain, glaucoma treatment NOVO NORDISK A/S (DK) 1993-11-09 US disclosed
US-5043345-A Cognition activators; alzheimer's disease NOVO NORDISK A/S (DK) 1991-08-27 US disclosed
US-5041455-A Stimulants of cognitive function in mammals NOVO NORDISK A/S (DK) 1991-08-20 US disclosed
EP-0384288-A2 Piperidine compounds and their preparation and use NOVO NORDISK A/S (DK) 1990-08-29 EP disclosed